vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and SOUTHERN FIRST BANCSHARES INC (SFST). Click either name above to swap in a different company.

SOUTHERN FIRST BANCSHARES INC is the larger business by last-quarter revenue ($31.8M vs $19.6M, roughly 1.6× STANDARD BIOTOOLS INC.). On growth, SOUTHERN FIRST BANCSHARES INC posted the faster year-over-year revenue change (26.1% vs -11.5%). SOUTHERN FIRST BANCSHARES INC produced more free cash flow last quarter ($29.9M vs $-23.1M). Over the past eight quarters, SOUTHERN FIRST BANCSHARES INC's revenue compounded faster (22.2% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

First Community Bankshares, Inc. is a $2.43 billion bank holding company and the parent company of First Community Bank of Bluefield, Virginia, in the United States. As of 2012 First Community Bank had 45 locations in Virginia, West Virginia, and North Carolina, and two locations operating as Peoples Community Bank in Tennessee. As of April 21, 2023, First Community had $3.6 billion in assets.

LAB vs SFST — Head-to-Head

Bigger by revenue
SFST
SFST
1.6× larger
SFST
$31.8M
$19.6M
LAB
Growing faster (revenue YoY)
SFST
SFST
+37.6% gap
SFST
26.1%
-11.5%
LAB
More free cash flow
SFST
SFST
$53.0M more FCF
SFST
$29.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
SFST
SFST
Annualised
SFST
22.2%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
SFST
SFST
Revenue
$19.6M
$31.8M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
40.1%
Net Margin
-177.4%
Revenue YoY
-11.5%
26.1%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
SFST
SFST
Q4 25
$31.8M
Q3 25
$19.6M
$31.1M
Q2 25
$21.8M
$28.6M
Q1 25
$40.8M
$26.5M
Q4 24
$25.2M
Q3 24
$22.1M
$23.8M
Q2 24
$22.5M
$23.1M
Q1 24
$45.5M
$21.3M
Net Profit
LAB
LAB
SFST
SFST
Q4 25
Q3 25
$-34.7M
$8.7M
Q2 25
$-33.5M
$6.6M
Q1 25
$-26.0M
$5.3M
Q4 24
Q3 24
$-26.9M
$4.4M
Q2 24
$-45.7M
$3.0M
Q1 24
$-32.2M
$2.5M
Gross Margin
LAB
LAB
SFST
SFST
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
SFST
SFST
Q4 25
40.1%
Q3 25
-168.5%
36.4%
Q2 25
-118.1%
30.0%
Q1 25
-80.8%
26.1%
Q4 24
27.3%
Q3 24
-120.9%
24.1%
Q2 24
-134.5%
17.0%
Q1 24
-132.2%
15.9%
Net Margin
LAB
LAB
SFST
SFST
Q4 25
Q3 25
-177.4%
27.8%
Q2 25
-153.7%
23.0%
Q1 25
-63.8%
19.9%
Q4 24
Q3 24
-122.0%
18.4%
Q2 24
-203.3%
13.0%
Q1 24
-70.6%
11.8%
EPS (diluted)
LAB
LAB
SFST
SFST
Q4 25
$1.19
Q3 25
$-0.09
$1.07
Q2 25
$-0.09
$0.81
Q1 25
$-0.07
$0.65
Q4 24
$0.69
Q3 24
$-0.07
$0.54
Q2 24
$-0.12
$0.37
Q1 24
$-0.27
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
SFST
SFST
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$368.7M
Total Assets
$539.6M
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
SFST
SFST
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
SFST
SFST
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
SFST
SFST
Q4 25
$368.7M
Q3 25
$399.7M
$356.3M
Q2 25
$424.5M
$345.5M
Q1 25
$454.6M
$337.6M
Q4 24
$330.4M
Q3 24
$489.3M
$326.5M
Q2 24
$510.3M
$318.7M
Q1 24
$577.3M
$315.3M
Total Assets
LAB
LAB
SFST
SFST
Q4 25
$4.4B
Q3 25
$539.6M
$4.4B
Q2 25
$557.0M
$4.3B
Q1 25
$579.6M
$4.3B
Q4 24
$4.1B
Q3 24
$681.5M
$4.2B
Q2 24
$708.7M
$4.1B
Q1 24
$777.7M
$4.1B
Debt / Equity
LAB
LAB
SFST
SFST
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
SFST
SFST
Operating Cash FlowLast quarter
$-22.2M
$30.5M
Free Cash FlowOCF − Capex
$-23.1M
$29.9M
FCF MarginFCF / Revenue
-118.1%
93.8%
Capex IntensityCapex / Revenue
4.5%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$62.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
SFST
SFST
Q4 25
$30.5M
Q3 25
$-22.2M
$14.5M
Q2 25
$-20.7M
$10.5M
Q1 25
$-30.3M
$7.6M
Q4 24
$25.6M
Q3 24
$-27.9M
$26.3M
Q2 24
$-39.0M
$4.0M
Q1 24
$-62.5M
$-2.9M
Free Cash Flow
LAB
LAB
SFST
SFST
Q4 25
$29.9M
Q3 25
$-23.1M
$14.4M
Q2 25
$-22.6M
$10.4M
Q1 25
$-35.3M
$7.4M
Q4 24
$24.8M
Q3 24
$-30.1M
$26.1M
Q2 24
$-41.0M
$3.9M
Q1 24
$-63.3M
$-3.2M
FCF Margin
LAB
LAB
SFST
SFST
Q4 25
93.8%
Q3 25
-118.1%
46.3%
Q2 25
-103.6%
36.3%
Q1 25
-86.6%
28.1%
Q4 24
98.2%
Q3 24
-136.4%
110.0%
Q2 24
-182.2%
16.8%
Q1 24
-138.9%
-15.0%
Capex Intensity
LAB
LAB
SFST
SFST
Q4 25
1.8%
Q3 25
4.5%
0.3%
Q2 25
8.7%
0.3%
Q1 25
12.4%
0.5%
Q4 24
3.1%
Q3 24
10.2%
0.8%
Q2 24
8.6%
0.4%
Q1 24
1.7%
1.3%
Cash Conversion
LAB
LAB
SFST
SFST
Q4 25
Q3 25
1.67×
Q2 25
1.59×
Q1 25
1.44×
Q4 24
Q3 24
6.01×
Q2 24
1.32×
Q1 24
-1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

SFST
SFST

Segment breakdown not available.

Related Comparisons